Review article

https://doi.org/10.2478/acph-2013-0022

Drug interactions with statins

ANIDA ČAUŠEVIĆ-RAMOSEVAC ; Bosnalijek, Pharmaceutical and Chemical Industry, Joint Stock Company, Sarajevo, Bosnia and Herzegovina
SABINA SEMIZ ; Faculty of Pharmacy, University of Sarajevo, Sarajevo, Bosnia and Herzegovina; Faculty of Engineering and Natural Sciences, International University of Sarajevo, Sarajevo, Bosnia and Herzegovina

Abstract

The 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase inhibitors (statins) are generally very well tolerated as monotherapy. Statins are associated with two important, adverse effects, asymptomatic elevation in liver enzymes and myopathy. Myopathy is most likely to occur when statins are administered with other drugs. The statins are substrates of multiple drug transporters (including OATP1B1, BCRP and MDR1) and several cytochrome P450 (CYP) enzymes (including CYP3A4, CYP2C8, CYP2C19, and CYP2C9). Possible adverse effects of statins can occurr due to interactions with concomitant use of drugs that substantially inhibit or induce their methabolic pathway. This review will summarize the most important interactions of statins.

Keywords

statins; drug interactions; cytochrome P450 (CYP) enzymes; drug transporters; adverse effects

Hrčak ID:

102048

URI

https://hrcak.srce.hr/102048

Publication date:

30.9.2013.

Visits: 7.953 *